2 completed, 1 active not recruiting, 1 withdrawn. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
Follow Primary Effusion Lymphoma: new trials by email Literature Review of Primary Effusion Lymphoma trials Research Report on Primary Effusion Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Lenalidomide, Rituximab, Prednisone - Primary Effusion Lymphoma, B-Cell Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2017-07-03 | 2026-11-12 |
| Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Pomalidomide, Rituximab, Prednisone - Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2014-08-15 | 2018-08-31 | |
| Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 107 | 2010-10-06 | 2023-11-21 |
Lymphoma, Primary Effusion (4) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Plasmablastic Lymphoma (2) · Burkitt Lymphoma (1) · HIV Infections (1) · Lymphoma, AIDS-Related (1) · Lymphoma, Follicular (1) · Lymphomatoid Granulomatosis (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Infections (2) · Lymphoma, B-Cell (2) · Virus Diseases (2) · Blood-Borne Infections (1) · Communicable Diseases (1) · DNA Virus Infections (1)
Cyclophosphamide (3) · Doxorubicin (3) · Etoposide (3) · Prednisone (3) · Rituximab (3) · Vincristine (3) · Bronchoscopy (1) · CT-P10 (1) · Disulfides (1) · Echocardiography (1) · Electrocardiography (1) · Endoscopy (1) · Immunoglobulin G (1) · Lenalidomide (1) · Nivolumab (1)
National Cancer Institute (NCI) (4)
United States (3)
Juan C Ramos (1) · Ramya Ramaswami, MBBS, MPH (1) · Stephen M Ansell (1) · Thomas S Uldrick, M.D. (1)
UM1CA121947 (1), UM1CA186686 (1), UM1CA186709 (1)